New Born Screening
Newborn Screening or Neonatal Screening is a preventive pediatric screening service performed to diagnose congenital or inborn errors of metabolism in order to identify patients and administrate treatment starting from the first weeks of life to reverse the prognosis. Early diagnosis and treatment correlates with significant reduction in mortality and associated disabilities for those affected.
Labsystems Diagnostics is the first company in the world to introduce fluorometric microplate based assay for phenylalanine for diagnosing phenylketonuria (PKU) in newborns and is the only company in the world to have an assay for the diagnosis of neonatal toxoplasmosis.
The company develops, manufactures and markets high quality enzyme immunoassays, molecular assays and Point of Care tests. Labsystems has the complete solution to newborn screening.